Ignite Creation Date:
2025-12-25 @ 1:24 AM
Ignite Modification Date:
2026-02-24 @ 5:08 AM
Study NCT ID:
NCT03861793
Status:
COMPLETED
Last Update Posted:
2024-03-05
First Post:
2019-02-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
Sponsor:
Mural Oncology, Inc
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Advanced Solid Tumors | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Alkermes | View |
| None | IL-2 | View |
| None | Interleukin-2 | View |
| None | Oncology | View |
| None | Immuno-oncology | View |
| None | Cytokine | View |
| None | ALKS 4230 | View |
| None | Pembrolizumab | View |
| None | Keytruda | View |
| None | PD-L1 | View |
| None | Solid tumors | View |
| None | Immunotherapy | View |
| None | nemvaleukin alfa | View |
| None | ovarian | View |
| None | Head and Neck | View |
| None | NSCLC | View |
| None | Non small cell lung cancer | View |
| None | lung cancer | View |
| None | Gastric | View |
| None | Gastric Cancer | View |
| None | Gastroesophageal Cancer | View |
| None | Gastroesophageal junction (GEJ) adenocarcinoma | View |
| None | GEJ Cancer | View |
| None | adenocarcinoma | View |